X

Strides Pharma Science Ltd Stock Analysis

Mid Cap
Evaluated by 2621 users | BSE: 532531 | NSE: STAR |
Pharmaceuticals & Drugs
Strides Arcolab, incorporated in 1990, is engaged in the manufacture of pharmaceutical dosage forms in branded as well generic categories. The dosages are manufactured in form of tablets, capsules, soft gelatin capsules, parenterals and semi-solids. The company manufactures soft gels and...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Strides Pharma Science Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation
 Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 4.68%5.61%8.53%21.65%9.19%6.55%2.06%21.86%3.99%4.11%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 5057507128519292,2221,3821,9551,5371,674
Y-o-Y Gr. Rt.-48.5%-5%19.5%9.2%139%-37.8%41.5%-21.4%8.9%
Adjusted EPS (Rs.) 6.9213.9122.4149.8626.6716.085.3698.7213.2413.36
Y-o-Y Gr. Rt.-101%61.1%122.5%-46.5%-39.7%-66.7%1741.8%-86.6%0.9%
Book Value per Share (Rs.) 243.14232.35232.62219.01247.18352.77360.5352.29362.84353.87
Adjusted Net Profit 4081.213229715914447.9884119120
Net Op. Cash Flow (Rs. Cr.) 48.110211.1-2.720783.141265.640149
Debt to Cash Flow from Ops 25.828.856.95-141.261.9518.593.919.2420.255.73
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Strides Pharma Science Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 14.3%12.5%6.6%8.9%
Adjusted EPS 7.6%-12.9%35.6%0.9%
Book Value per Share 4.37.4-0.6-2.5
Share Price 9.7% -3.2% 3.7% 130.2%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Dec'10Dec'11Dec'12Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 3.435.879.6524.7310.236.21.527.633.693.72
Operating Profit Margin (%) 14.5520.3219.61714.4112.148.17.369.8213.46
Net Profit Margin (%) 7.9210.8318.5134.917.096.473.4745.187.717.15
Debt to Equity 0.890.660.460.290.270.490.50.190.250.27
Working Capital Days 861933726464783293405295383343
Cash Conversion Cycle 4039797591571233993112
Entity Percentage Holding
Promoters 29.69%
Institutions 42.24%
Non-Institutions 28.07%
Pledged *23.5419.6328.9116.3113.0251.2948.2050.9346.8437.04
* Pledged shares as % of Promoter's holding (%)

MoneyWorks4Me analysed the past 10-year performance of Strides Pharma Science Ltd and arrived at the following conclusion:

Past 10 year's financial track record indicates that Strides Pharma Science Ltd is a below average quality company. However, for specific investment actions please connect with your investment advisor.

The 5-year analysis of Strides Pharma Science Ltd's performance infers:

Strides Pharma Science Ltd earnings have declined by -12.9%, whereas share price has depreciated -3.2% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Strides Pharma Science Ltd share prices over the last 10 years. Here is what we found out:

Strides Pharma Science Ltd share price has depreciated 8.1% annually over the past ten years.

Strides Arcolab, incorporated in 1990, is engaged in the manufacture of pharmaceutical dosage forms in branded as well generic categories. The dosages are manufactured in form of tablets, capsules, soft gelatin capsules, parenterals and semi-solids.

The company manufactures soft gels and steriles. It has 13 manufacturing facilities located across the world -- in India, Singapore,

Strides Arcolab, incorporated in 1990, is engaged in the manufacture of pharmaceutical dosage forms in branded as well generic categories. The dosages are manufactured in form of tablets, capsules, soft gelatin capsules, parenterals and semi-solids.

The company manufactures soft gels and steriles. It has 13 manufacturing facilities located across the world -- in India, Singapore, Brazil, Mexico, Poland and Italy.

These facilities have received approval from various regulatory authorities namely MHHRA, TGA, MCC, ANVISA. The company’s Bangalore plant is pre-qualified by WHO to manufacture of HIV/ AIDS and anti-TB drugs.

The company is among the top 5 soft gelatin capsule manufacturers in world.

Strides Acrolab has partnered with major pharmaceutical companies located in Australia, South Africa, Europe, and USA.

The company has a joint venture with Akorn -- Akorn-Strides, LLC -- to develop liquid, lyophilized and dry powder formulations of generic injectable products targeting several therapeutic markets.

Products

Soft gel capsules- The company manufactures range of soft gel in category of nutraceuticals, Rx, specialty OTCs and immunosuppressants.

Steriles- Under this, it offers its products in therapeutic segments that includes beta-lactams and cephalosporins. The company manufactures striles in various forms such as prefill syringes, ampoules, vials and penicillins.

Outlook

Akorn-Strides, LLC has received approval from the US Food and Drug Administration for two Abbreviated New Drug Applications (ANDAs) for Sterile Vancomycin HCl USP, 500 mg/vial, 1 g/vial and Sterile Vancomycin HCl USP, 5 g/vial Pharmacy Bulk Package.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback